Equity to Asset ratio is calculated as total stockholders equity divided by total asset. CTI BioPharma's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $-25.35 Mil. CTI BioPharma's Total Assets for the quarter that ended in Mar. 2023 was $112.27 Mil.
Therefore, CTI BioPharma's Equity to Asset Ratio for the quarter that ended in Mar. 2023 was -0.23.
The historical rank and industry rank for CTI BioPharma's Equity-to-Asset or its related term are showing as below:
CTIC'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.37 Med: 0.41 Max: 0.82
Current: -0.23
During the past 13 years, the highest Equity to Asset Ratio of CTI BioPharma was 0.82. The lowest was -0.37. And the median was 0.41.
CTIC's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.67
vs CTIC: -0.23
CTI BioPharma Equity-to-Asset Historical Data
The historical data trend for CTI BioPharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CTI BioPharma's Equity-to-Asset
For the Biotechnology subindustry, CTI BioPharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CTI BioPharma's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CTI BioPharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where CTI BioPharma's Equity-to-Asset falls into.
CTI BioPharma Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
CTI BioPharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
CTI BioPharma Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of CTI BioPharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
CTI BioPharma (CTI BioPharma) Business Description
CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTIC has been successfully added to your 